Browse News
Filter News
Found 4,642 articles
-
Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
8/14/2018
Conference call to be held at 9:00 AM ET on Wednesday, August 15, 2018
-
CRISPR, the gene editing technique that promises designer babies, to end to all disease as we know it, and biohacking where individuals could change their own genome to include that of fluorescent jellyfish or lobster claws, seems to have more problems than originally thought.
-
BioLineRx Reports Second Quarter 2018 Financial Results
8/13/2018
BioLineRx Ltd. reports its financial results for the second quarter ended June 30, 2018.
-
Sutro and The Leukemia & Lymphoma Society Partner on Lymphoma and Multiple Myeloma Treatment
8/13/2018
Sutro Biopharma, Inc., and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma.
-
GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
8/9/2018
Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia (AML) patients eligible for intensive chemotherapy
-
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
8/8/2018
The applications seek to update the Prescribing Information and Summary of Product Characteristics to provide health care professionals with the option to split the first infusion of DARZALEX® over two consecutive days.
-
OncoPep Announces a Phase 1b Clinical Trial of Its Multi-Peptide Cancer Vaccine PVX-410 in Combination with Citarinostat for Smoldering Multiple Myeloma
8/8/2018
OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating the safety and tolerability of PVX-410.
-
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202
8/8/2018
On August 8, 2018 Beijing time I-Mab Biopharma and MorphoSys AG announced today that I-Mab has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.
-
Women Score Top Marks in The Leukemia & Lymphoma Society of Canada's 2018 Research Awards
8/8/2018
Female scientists lead scorers among 32 grant awardees in annual research competition held by Canada's only nonprofit health agency dedicated to all blood cancers.
-
Medigene AG: Medigene Reports Results for the First Half of 2018
8/8/2018
Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, reports today on its business and financial results for the first half of 2018. In the first six months of 2018, Medigene significantly increased its revenue and reduced its loss. The company improves the financial guidance for the full year 2018.
-
Halozyme Reports Second Quarter 2018 Results
8/7/2018
Revenue of $35.2 Million Includes a 36 Percent Increase in Royalty Revenue on a Reported Basis
-
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
8/7/2018
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial.
-
Teneobio and Poseida Expand Their Partnership to Develop UniDabs™ for Advanced CAR-T Therapies
8/7/2018
Teneobio, Inc., a next generation multi-specific antibody therapeutics company, and Poseida Therapeutics, Inc., a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, announced today a new research collaboration and licensi... -
Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study
8/6/2018
Immix Biopharma, Inc. announced that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110.
-
Ligand Reports Second Quarter 2018 Financial Results
8/6/2018
Updates 2018 Full Year Guidance
-
August 3 Research Roundup: Cannabidiol and Pancreatic Cancer, Metformin, Thalidomide and More
8/3/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
The Leukemia & Lymphoma Society Greater Bay Area Chapter to Host World Class Sailing Event with Notable Speakers
8/2/2018
The Leukemia & Lymphoma Society's (LLS) Greater Bay Area Chapter will host the Leukemia Cup Regatta on October 20 and 21 at the Corinthian Yacht Club in Tiburon, CA.
-
GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
8/2/2018
GlycoMimetics, Inc. announced that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET.
-
Tempus to Participate in the NCI-MATCH Clinical Trial
8/2/2018
Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial
-
Laekna, headquartered in Shanghai, China, signed a deal with Novartis Pharma AG for exclusive worldwide rights to two oral Novartis clinical-stage cancer drugs.